Establishment and Evaluation of Prenatal Prevention and Treatment Strategy for NARDS
Launched by THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY · Jan 1, 2024
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how to prevent and treat a serious lung condition called Neonatal Acute Respiratory Distress Syndrome (NARDS) in newborns. Researchers have created a model that predicts which babies are at higher risk for developing NARDS based on certain factors during pregnancy. If a pregnant woman has an 80% or higher chance of her baby developing this condition, she may receive a treatment called antenatal corticosteroids (ACS) before giving birth. This treatment aims to help the baby’s lungs develop better and reduce the risk of breathing problems.
To be eligible for this trial, pregnant women must have a high probability (over 80%) of their baby developing NARDS and agree to receive the ACS treatment. They will need to provide consent to participate. Participants can expect to have their baby’s health closely monitored, including tests right after birth to measure lung function and any breathing difficulties. The trial will compare the health outcomes of babies who received the treatment with those who did not, to see how effective the ACS is in preventing serious lung issues. This research is important because it aims to improve the care of newborns at risk for breathing problems, potentially saving lives and improving long-term health outcomes.
Gender
FEMALE
Eligibility criteria
- • A predictive model for neonatal acute respiratory distress syndrome was established based on perinatal risk factors.
- Inclusion Criteria:
- • 1. The pregnant women with a probability greater than 80% in the prediction model of neonatal acute respiratory distress syndrome and agreed to ACS intervention.
- • 2. Obtaining patient consent.
- Exclusion Criteria:
- • 1. the pregnant women with a probability of less than 80% in the neonatal acute respiratory distress syndrome prediction model.
- • 2. The patient refuses.
About The Second Affiliated Hospital Of Chongqing Medical University
The Second Affiliated Hospital of Chongqing Medical University is a leading healthcare institution dedicated to advancing medical research and patient care through innovative clinical trials. As a prominent academic hospital in China, it combines cutting-edge medical technology with a strong emphasis on education and training for healthcare professionals. The hospital is committed to conducting high-quality, ethically sound clinical research that contributes to the development of new therapies and enhances healthcare outcomes. With a multidisciplinary team of experts, the Second Affiliated Hospital fosters collaboration and strives to address critical health challenges through rigorous scientific investigation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chongqing, , China
Patients applied
Trial Officials
Li Wang, MD,PhD
Study Chair
The Second Affiliated Hospital of Chongqing Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported